arrow
S

Sébastien Perreault

University of Montreal and CHU Sainte-Justine
H指数:32
被引数:4,143

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

TRAM-01:曲美替尼治疗1型神经纤维瘤病伴丛状神经纤维瘤的儿科患者Ⅱ期研究

2026-05-190
OA
Proton beam therapy for cancer in children and adolescents: A retrospective Canadian paediatric tumour consortium study

儿童和青少年癌症的质子束疗法:一项回顾性加拿大儿科肿瘤协作组研究

2026-04-300
PRE
Parent and child physical activity as possible predictors of quality of life in pediatric brain tumor patients: a dyadic analysis

父母与子女的体育活动作为预测儿科脑肿瘤患者生活质量的可能预测因子:一项双向分析

2025-12-310
PRE
Clinical stability following tovorafenib treatment in relapsed/refractory pediatric low-grade glioma: updated results from the phase 2 FIREFLY-1 trial

托伐拉芬治疗后复发/难治性儿童低级别胶质瘤的临床稳定性:更新来自2期FIREFLY-1试验的结果

2025-11-010
OAAI
High-resolution proteomic analysis of medulloblastoma clinical samples identifies MYC immunohistochemistry as a powerful outcome predictor outperforming genetic amplification detection

高分辨率蛋白质组学分析对髓母细胞瘤临床样本的研究确定了MYC免疫组化是一种强大的预后预测因子,其预测性能优于基因扩增检测。

2025-11-010
PRE
Enhancing Medulloblastoma Classification: Integrating IHC and DNA Methylation Data from the SJMB12 Clinical Trial

增强髓母细胞瘤分类:整合SJMB12临床试验的IHC和DNA甲基化数据

2025-11-010
OAAI
Molecular characterization of the SJMB12 clinical trial for children and young adults with newly diagnosed medulloblastoma

SJMB12临床试验的分子特征分析:针对新诊断髓母细胞瘤的儿童及青少年患者

2025-11-010
PRE
The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma

参与者在进行MEK抑制剂临床试验的丛状神经纤维瘤中致病性NF1变异的谱系

2025-10-150
PRE
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2025-04-160
OA
Germline analysis of an international cohort of pediatric diffuse midline glioma patients

对国际队列儿童弥漫性中线胶质瘤患者的生殖系分析

2025-03-120
PRE
High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor

对髓母细胞瘤临床样本的高分辨率蛋白质组学分析鉴定出耐药亚组以及MYC免疫组化作为强有力的预后预测因子

2025-02-180
PRE
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

在FIREFLY-1试验中,托瓦雷芬尼(tovorafenib)这种II型RAF抑制剂对复发性/难治性视神经通路胶质瘤患儿的放射学和视觉反应。

2024-12-190
PRE
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
2024-11-110
PRE